Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie Ann Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017

Cited by 585 works. doi:10.1016/s1470-2045(17)30717-9

Authors

References